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Abstract
The effects of growth hormone (GH) in regulating the
expression of the hepatic and renal GH and insulin-like
growth factor (IGF) system were studied by administering
a novel GH receptor antagonist (GHRA) (B2036-PEG)
at different doses (0, 1·25, 2·5, 5 and 10 mg/kg/day) to
mice for 7 days. No differences were observed in the
groups with respect to body weight, food consumption or
blood glucose. However, a dose-dependent decrease was
observed in circulating IGF-I levels and in hepatic and
renal IGF-I levels at the highest doses. In contrast, in the
5 and 10 mg/kg/day GHRA groups, circulating and
hepatic transcriptional IGF binding protein-3 (IGFBP-3)
levels were not modified, likely resulting in a significantly
decreased IGF-I/IGFBP-3 ratio. Hepatic GH receptor
(GHR) and GH binding protein (GHBP) mRNA levels
increased significantly in all GHRA dosage groups.
Endogenous circulatory GH levels increased significantly
in the 2·5 and 5 mg/kg/day GHRA groups. Remarkably,
increased circulating IGFBP-4 and hepatic IGFBP-4
mRNA levels were observed in all GHRA administration
groups. Renal GHR and GHBP mRNA levels were not
modified by GHRA administration at the highest doses.
Also, renal IGFBP-3 mRNA levels remained unchanged
in most GHRA administration groups, whereas IGFBP-1,
-4 and -5 mRNA levels were significantly increased in the
5 and 10 mg/kg/day GHRA administration groups.
In conclusion, the effects of a specific GHR blockade on
circulating, hepatic and renal GH/IGF axis reported here,
may prove useful in the future clinical use of GHRAs.
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Introduction
The growth hormone (GH)/insulin-like growth factor
(IGF) axis constitutes a complex system of peptides in the
circulation, extracellular space and in most tissues. The
classical endocrine effect of pituitary-secreted GH is the
induction of IGF-I synthesis in various organs. The liver is
believed to be the major source of circulating IGF-I
which, in turn, is a negative feedback signal on GH
secretion (Namba et al. 1989, Yamasaki et al. 1991).
IGF-I is a member of the IGF system that also consists
of IGF-II, two types of IGF receptors and six different IGF
binding proteins (IGFBPs) (Kelley et al. 1996). In addition,
four IGFBP-related proteins have been described (Baxter
et al. 1998).
The GH/IGF axis is important for normal cell growth
and differentiation, but has also been shown to be involved
in pathophysiological processes. Recently, a series of GH
antagonists has been developed that specifically block the
GH receptor (GHRAs) (Chen et al. 1991b, 1994). These
GHRAs may be used as intervention in various diseases
where GH action is known to play a pathophysiological
role (e.g. acromegaly) (Trainer et al. 2000) or is suspected
of being involved in organ specific damage (e.g. diabetic
kidney disease) (Flyvbjerg et al. 1999a, Segev et al.
1999).
In order to get more detailed information about the
effects of specific GH receptor (GHR) blockade on
circulating and local components of the GH/IGF axis, a
GHRA with an enhanced affinity for the human GHR
(B2036-PEG) was studied at different doses in mice. The
effects of GHRA administration on the expression of the
GH/IGF components were investigated in the liver,
thought to be the major regulator of circulating IGFs, and
in the kidney, as various kidney diseases may be potential
targets for GHRA treatment.
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Materials and Methods
Animals
Adult female Balb/C(a) mice with initial body weights of
16·40·2 g (Bomholtgaard, Ry, Denmark) were used in
the study. The animals were housed 7–8 per cage on white
special spanwall bedding. They were fed a standard
laboratory diet (Altromin No. 1310, Altromin, Lage,
Germany), had free access to water and were kept at
constant temperature (211 C), humidity (555%)
and under a 12-h light, 12-h darkness cycle (lights on from
0700 h to 1900 h). The study complied with Danish
regulations for the care and use of laboratory animals.
Study design
The mice were randomly allocated into five groups of
eight animals: (1) animals injected on days 0, 2, 4 and 6
with 0·154 mol/l NaCl, the vehicle for the other treat-
ments (control group); (2) animals injected on days 0, 2, 4
and 6 with 2·5 mg/kg human GHR antagonist (GHRA):
B2036-PEG (1·25 mg/kg/day GHRA group); (3) animals
injected on days 0, 2, 4 and 6 with 5 mg/kg GHRA
(2·5 mg/kg/day GHRA group); (4) animals injected on
days 0, 2, 4 and 6 with 10 mg/kg GHRA (5 mg/kg/day
GHRA group); (5) animals injected on days 0, 2, 4 and 6
with 20 mg/kg GHRA (10 mg/kg/day GHRA group).
Human GHRA (B2036-PEG) was kindly provided by
Sensus Drug Development Corporation (Austin, TX,
USA) (Fuh et al. 1992). The molecule has a modification
in the first GHR binding site resulting in a 30–50 times
increased affinity for the human GHR. In addition, in the
second GHR binding site, amino acid 120 is modified
preventing GHR dimerization (Chen et al. 1991c).
GHRA was provided in a pegylated formula to warrant
prolonged biological action of the molecule (Clark et al.
1996). The GHRA was dissolved in 0·154 mol/l NaCl
and injected s.c. on days 0, 2, 4, and 6 in an injection
volume of 0·5 ml. The animals were weighed and their
food consumption and blood glucose was determined on
days 0, 2, 4, and 7. On day 7, the animals were
anesthetized with pentobarbital (50 mg/kg i.p.) and non
fasting blood samples were collected exactly 5 min later
from the retrobulbar plexus through heparinized capillary
tubes under light ether anesthesia. The serum samples
were kept at80 C for later analysis. Whole liver and the
left kidney were removed and snap frozen in liquid
nitrogen.
Blood glucose
Blood glucose was measured in unanesthetized animals in
tail vein blood by Haemoglucotest 1–44 and Reflolux II
reflectance meter (Boehringer-Mannheim, Mannheim,
Germany).
Serum GH and IGF-I, and hepatic and kidney IGF-I
determinations
Serum GH was measured by a radioimmunoassay (RIA) as
described previously (Flyvbjerg et al. 1999a). Potential
cross-reactivity of the GHRA (B2036-PEG) with the
rodent specific GH assay was precluded, as addition in the
assay of the GHRA at multiple concentrations (over a
range from 0·5–5000 µg/l) did not reveal any significant
binding. Serum IGF-I was measured after extraction using
acid-ethanol (Flyvbjerg et al. 1999a). The intra-assay and
interassay coefficients of variation (CV) were 5% and 10%
respectively. Tissue extraction of renal and hepatic IGF-I
was performed according to D’Ercole et al. (1984) and
corrected for the contribution of entrapped serum IGF-I
(Flyvbjerg et al. 1992b).
Serum IGFBPs
SDS-PAGE and Western ligand blotting (WLB) analysis
were executed according to the method of Hossenlopp
et al. (1986) as described previously (Flyvbjerg et al.
1992a).
Gene expression of GH and IGF system (mRNA) in tissues
Gene expression of IGFBP-1 to -6 (mRNA) was
measured by Northern blot analysis. Total RNA was
extracted from kidney and liver samples by the guanidin-
ium thiocyanate method (Chomczynski & Sacchi 1987).
Glyoxylated-RNA samples were electrophoresed in 1%
agarose gels submerged in 10 mM sodium phosphate pH
7·2 and transferred to nylon membranes (Hybond N+,
Amersham, ’s Hertogenbosch, The Netherlands). Filters
were hybridized with 1–2106 c.p.m. per ml 32P-labeled
cDNA fragments encoding for each of the six mouse
IGFBPs (Schuller et al. 1994), mouse IGF-I and -II (kindly
provided by Dr G I Bell, Howard Hughes Institute,
Chicago, IL, USA), rat IGF-I receptor (kindly provided
by Dr H Werner and Dr D LeRoith, National Institutes of
Health, Bethesda, MD, USA), GHR, GHBP (Mathews
et al. 1989) and glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) at 65 C according to the method of
Church & Gilbert (1984).
Quantification
Autoradiographs of WLBs were scanned using a laser
densitometer (Shimadzu model CS 90001 PC, Shimadzu
Europe GmbH, Duisburg, Germany) and the relative
densities of the bands expressed in pixels. Northern
blots were scanned on a Phosphor Imager (Molecular
Dynamics, Sunnyvale, CA, USA) and quantified using
ImageQuant software. All measured mRNA results were
expressed relative to GAPDH mRNA levels.
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Statistical analysis
Data were examined for distribution, variance homogen-
eity (F-test) and analyzed by one-way analysis of variance
followed by pair-wise comparisons with the least-
significant difference method. All data are expressed as
means..., with n indicating the number of mice
studied. P values less than 0·05 are considered significant.
Results
Body weight and organ weights
The body weights of the different study groups at the
beginning (day 0) and end (day 7) of the experimental
period were determined. The mean body weights on day
0 were 16·40·2 g with no differences between the
groups. At day 7, mean body weight increased to
18·90·3 g in control animals with no differences in the
different groups (data not shown). At the end of the
experimental period, liver and kidney weights were
determined. Liver weight and the weight of the kidneys in
the control group were 92635 mg and 2373 mg
respectively. The GHRA administration regimen demon-
strated no significant effects on the weight of liver or
kidneys (data not shown).
Food consumption and blood glucose
Food consumption over 24 h was measured during the
study period on a group basis. Mean food intake per mouse
of the control group was 4·20·1 g per 24 h. Food
consumption did not differ significantly during the exper-
imental period in any of the groups (data not shown).
Blood glucose values were measured in all animals at the
end of the experimental period and did not change
significantly in any of the experimental groups (data not
shown).
Serum IGF-I and GH
At the end of the study period serum IGF-I levels were
determined in all groups (Fig. 1A). Compared with
placebo control levels, in the 1·25 mg GHRA group
serum IGF-I levels were unchanged, whereas in the 2·5, 5
and 10 mg GHRA groups serum IGF-I levels were
reduced to 75% (P=0·006), 70% (P=0·001) and 51%
(P<0·001) of control values respectively (Fig. 1A). Com-
pared with the other groups significant and dose-
dependent decreases in circulatory IGF-I levels were
observed (1·25 mg versus 2·5 mg GHRA group, P<0·008;
5 mg versus 10 mg GHRA group, P=0·011). Figure 1B
shows serum GH levels in the five experimental groups by
the end of the study (day 7). It has been demonstrated
previously that barbital anesthesia induces a marked rise in
GH levels that lasts for up to 90 min (Takahashi et al.
1971). Therefore, the endogenous GH levels given in
Fig. 1B are stimulated values. Increased serum GH levels
amounting to 183% (P=0·003) and 145% (P=0·01) of
control values were seen in the 2·5 mg GHRA and 5 mg
GHRA groups respectively.
Serum IGFBPs
Using WLB, four distinct bands were obtained. A double
band at 38–42 kDa representing IGFBP-3, a single
30 kDa band (IGFBP-1 and -2) and a 24 kDa band
identified as IGFBP-4.
GHRA administration did not affect IGFBP-3 levels
with the exception of the group receiving 2·5 mg GHRA.
In this group IGFBP-3 levels were significantly decreased
to 78% of control levels (P=0·04) (Fig. 1C). Circulatory
30 kDa (IGFBP-1 and -2) levels were unchanged in all
groups (Fig. 1C). IGFBP-4 levels were significantly
increased in the 1·25, 2·5 and 5 mg GHRA groups to
143% (P=0·008), 142% (P=0·04) and 159% (P=0·001) of
control levels. In the 10 mg GHRA group, IGFBP-4
levels were near significantly increased to 125% (P=0·06)
of control levels (Fig. 1C). In the 5 and 10 mg GHRA
groups the calculated ratio of IGF-I to IGFBP-3 was
significantly decreased to 71% (P=0·001) and 53%
(P<0·001) of control values.
Hepatic GH/IGF system expression
GHRA administration for 7 days significantly increased
hepatic GHR mRNA expression at all doses tested
(Fig. 2B). GHBP mRNA expression was dose-
dependently increased in the 1·25 mg, 2·5 mg and
5 mg GHRA groups (control versus 1·25 mg GHRA
group, P<0·001; 1·25 mg versus 2·5 mg GHRA group,
P<0·001; 2·5 mg versus 5 mg GHRA group, P=0·044).
A representative Northern blot is given in Fig. 2A.
Hepatic IGF-I protein levels, however, demonstrated a
tendency to decline in all GHRA administration groups,
only reaching significance in the 10 mg GHRA group
(P=0·004) (see Fig. 4A). Hepatic IGF-I mRNA levels
(predominantly 1·2 kb and 7 kb) also had a tendency to
decline in all GHRA administration groups reaching
significance in the 2·5 mg GHRA (P=0·01) and 10 mg
GHRA (P=0·05) groups (Fig. 2C).
Compared with control animals, hepatic IGFBP-1
mRNA levels had a tendency to increase, only reach-
ing significance in the 2·5 mg GHRA group (P<0·03)
(Fig. 2D). Hepatic IGFBP-2 mRNA levels were signifi-
cantly decreased in the 1·25, 2·5 and 5 mg GHRA groups
(P<0·001, P=0·002 and P=0·001 respectively) (Fig. 2D).
IGFBP-3 mRNA levels were unchanged during GHRA
administration, whereas IGFBP-4 mRNA levels were
significantly increased in all GHRA administration groups
(Fig. 2D). Hepatic IGFBP-5 and -6, IGF-II and IGF-I
receptor mRNA levels were not detectable in any of the
groups.
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Renal GH/IGF system expression
GHRA administration did not modify renal GHR mRNA
levels except for the 1·25 mg GHRA group where a
significantly decreased GHR mRNA level was observed
(P=0·03) (Fig. 3B). A representative Northern blot is
given in Fig. 3A.
GHRA administration also did not modify renal GHBP
mRNA levels in most of the groups. Only the 10 mg
GHRA group demonstrated a significantly increased
GHBP level (P=0·005) (Fig. 3B).
Compared with the placebo control, in the 5 and 10 mg
GHRA groups renal IGF-I protein levels significantly
Figure 1 Circulatory levels of (A) IGF-I, (B) GH, and (C) IGFBP in adult mice injected for
7 days with placebo (open bars), 1·25 mg/kg/day (broad-hatched bars), 2·5 mg/kg/day
(cross-hatched bars), 5 mg/kg/day (narrow-hatched bars) and 10 mg/kg/day (solid bars)
GHRA B2036-PEG. Values are meansS.E.M. (n=8). *P=0·04, **P<0·01, ***P0·001,
statistical significance level between the indicated GHRA group and the placebo control.
#P=0·008 significance level between the 1·25 mg and the 2·5 mg GHRA group; &P=0·011
significance level between the 5 mg and 10 mg GHRA group.
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Figure 2 (A) Representative mRNA expression
pattern of GHR, GHBP, IGFBP-4 and GAPDH in
livers of adult mice injected for 7 days with
placebo, 1·25, 2·5, 5 and 10 mg/kg/day GHRA
B2036-PEG. (B-D) Relative hybridization of
(B) GHR, GHBP mRNA, (C) IGF-I mRNA, and
(D) IGFBP-1, -2, -3, -4 mRNA in liver of adult
mice injected for 7 days with placebo (open
bars), 1·25 mg/kg/day (broad-hatched bars),
2·5 mg/kg/day (cross-hatched bars),
5 mg/kg/day (narrow-hatched bars) and
10 mg/kg/day (solid bars) GHRA B2036-PEG.
Values are based on quantitations of Northern
blots, compensated for RNA loading differences.
Values are represented as meansS.E.M. (n=8)
and expressed relative to the placebo control.
*P0·05, **P0·01, ***P0·001, statistical
significance level between the indicated GHRA
group and the placebo control. #P<0·001
significance level between the 1·25 mg and the
2·5 mg GHRA group; &P=0·044 significance
level between the 2·5 mg and 5 mg GHRA
group.
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Figure 3 (A) Representative mRNA
expression pattern of GHR, GHBP,
IGFBP-4 and GAPDH in kidneys of adult
mice injected for 7 days with placebo,
1·25, 2·5, 5 and 10 mg/kg/day GHRA
B2036-PEG. (B and C) Relative
hybridization of (B) GH receptor, GHBP,
IGF-I receptor and IGFBP-1 mRNA and
(C) IGFBP-2, -3, -4 and -5 mRNA in
kidneys of adult mice injected for 7 days
with placebo (open bars),
1·25 mg/kg/day (broad-hatched bars),
2·5 mg/kg/day (cross-hatched bars),
5 mg/kg/day (narrow-hatched bars) and
10 mg/kg/day (solid bars) GHRA
B2036-PEG. Values are based on
quantitations of Northern blots,
compensated for RNA loading
differences. Values are represented as
meansS.E.M. (n=8) and expressed
relative to the placebo control. *P=0·05,
**P0·03, ***P0·005, statistical
significance level between the indicated
GHRA group and the placebo control.
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decreased (P=0·02 and P=0·005 respectively) (Fig. 4B).
IGFBP-1 and -3 mRNA levels were not modified by
GHRA administration except for the 5 mg GHRA
administration group where a significant increase was
observed (P=0·03 and P=0·005 respectively) (Fig. 3C).
IGFBP-2 mRNA levels decreased dose-dependently with
increasing GHRA concentrations which, however, only
reached significance in the 2·5 and 10 mg GHRA groups
(P=0·03 and P=0·005 respectively) (Fig. 3C). IGFBP-4
mRNA levels significantly increased in the 5 and 10 mg
GHRA groups (P=0·004 and P=0·03 respectively) and
IGFBP-5 mRNA levels significantly increased in the 2·5,
5 and 10 mg GHRA groups (P=0·03, P=0·01 and
P=0·05 respectively) (Fig. 3C). Renal IGF-I receptor
expression did not significantly change with any of the
treatments. Renal IGF-I, IGF-II and IGFBP-6 mRNA
levels were not detectable in any of the groups.
Discussion
In the present study, for the first time, the specific
blockage of GH at the organ level was studied using a
novel GHRA (B2036-PEG). B2036-PEG is a member of
a GHRA family recently developed for the human GHR
that retained its activity in mice. Studies using GHRAs
in vitro demonstrated high affinity binding to the GH
receptor (Chen et al. 1991b,c, Fuh et al. 1992). Transgenic
animals expressing GHRAs phenotypically resembled
dwarf animals with reduced circulating IGF-I levels (Chen
et al. 1990, 1991a). When GHRA transgenic animals were
made diabetic, protection to GH- and IGF-I-induced
renal damage was observed (Chen et al. 1995, 1996).
Furthermore, GHRA treatment protected diabetic mice
from renal damage (Flyvbjerg et al. 1999a, Segev et al.
1999) and abolished compensatory renal growth in
uninephrectomized mice (Flyvbjerg et al. 1999b).
To elucidate further the effects of GHRA, the present
study was performed with exogenous administration of a
long-acting formula of GHRA at increasing doses in adult
animals. The effects on body weight and on the circulat-
ing, hepatic and renal GH and IGF systems were analyzed.
In our study, increasing GHRA doses proportionally
decreased circulating and hepatic IGF-I levels. In contrast,
circulatory IGFBP-3 levels remained constant. The IGF-I
and IGFBP-3 serum values matched hepatic mRNA
levels as a dose-dependent decrease in hepatic IGF-I
mRNA values was observed, whereas the IGFBP-3
mRNA levels were unchanged at any of the GHRA doses
used. In the circulation, this might indicate a decrease in
IGF-I bioavailability. In rodents, there is evidence that
serum IGFBP-3 is regulated directly by IGF-I and is
independent of GH (Clemmons et al. 1989, Camacho-
Hubner et al. 1991). However, in our study circulatory
IGFBP-3 protein and hepatic IGFBP-3 mRNA levels
remained unchanged despite increased GH and decreased
Figure 4 (A) Hepatic and (B) renal IGF-I protein levels in adult mice injected for 7 days with
placebo (open bars), 1·25 mg/kg/day (broad-hatched bars), 2·5 mg/kg/day (cross-hatched
bars), 5 mg/kg/day (narrow-hatched bars) and 10 mg/kg/day (solid bars) GHRA B2036-PEG.
Values are meansS.E.M. (n=8). *P=0·02, **P0·005, statistical significance level between
the indicated GHRA group and the placebo control.
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IGF-I levels. The latter finding is in contrast to the
human, where serum IGFBP-3 levels directly reflected
GH levels (Blum et al. 1993). In addition, patients lacking
a functional GHR demonstrated high serum GH and low
serum IGF-I and IGFBP-3 levels (Cotterill et al. 1992,
Gargosky et al. 1993). The reasons for these differences in
serum IGFBP-3 regulation are unclear.
GHRA administration significantly increased circula-
tory GH levels, although at the highest GHRA concen-
tration, GH levels were decreased to control values. We
cannot readily explain this latter observation. As expected,
the increased blocking of the GHRs was reflected by a
dose-dependent decrease in circulatory IGF-I levels.
Therefore, a dose-dependent increase in circulating GH
levels was expected. It could be argued that, due to
cross-reactivity of the GHRA and GH, the GHRA
interfered in our GH assay. However, this possibility had
to be excluded as we could not demonstrate any cross-
reactivity between the human GHRA and the mouse GH
in the rodent specific RIA used for the measurements of
circulatory GH levels. Furthermore, one could argue that
a single GH determination is not the best estimate of GH
secretion. However, as shown before, a single barbital-
stimulated GH measurement may be used as an estimate of
GH levels (Takahashi et al. 1971).
GHRA administration significantly increased hepatic
GHR and GHBP mRNA levels, whereas renal GHR and
GHBP mRNA levels did not change significantly. These
results are in agreement with other studies examining renal
GHR/GHBP mRNA levels (Chen et al. 1997, Flyvbjerg
et al. 1999b, Segev et al. 1999). Our study may represent
a compensatory upregulation of the GHR gene expression
in response to the functional blockade of the GHR by the
GHRA. However, in contrast to our findings, Chen et al.
(1997) using GHRA expressing transgenic mice did not
observe increased hepatic GHR/GHBP mRNA expres-
sion although strongly enhanced liver GHR and serum
GHBP protein levels were found in these same GHRA
transgenic animals (Chen et al. 1997, Sotelo et al. 1998).
In GH-deficient dwarf rats, decreased renal IGF-I
mRNA and increased renal IGFBP-1 mRNA levels were
demonstrated that were normalized with exogenous GH
administration (Kobayashi et al. 1995). In our study,
increased GHRA doses did not have an effect on circula-
tory 30 kDa IGFBPs or hepatic and renal IGFBP-1
mRNA levels. Remarkably, GHRA administration did
increase circulatory IGFBP-4 protein, hepatic IGFBP-4
mRNA and, at higher doses, renal IGFBP-4 mRNA
levels also. This stimulation of IGFBP-4 expression, in
addition to the decrease in the IGF-I/IGFBP-3 ratio, may
lead to a further reduction in IGF-I bioavailability in
GHRA-treated animals. Kobayashi et al. (1995) also
demonstrated increased IGFBP-4 mRNA levels in
dwarf rats that, however, were not influenced by GH
administration. Therefore, multiple mechanisms may be
operative in regulating the expression of this gene.
In summary, in this study we demonstrated that admin-
istration of a specific GHRA dose-dependently decreased
hepatic and serum IGF-I with no effect on the expression
of hepatic or renal IGFBP-1 and -3 levels, while stimu-
lating hepatic and circulatory IGFBP-4 levels, likely
creating a significant decrease in IGF-I bioavailability. Our
findings provide a framework for understanding the use-
fulness of GHRA as a therapeutic drug. GHRA treatment
may be beneficial in inhibiting the GH/IGF-I axis in
diseases in which its involvement is implicated, such as
acromegaly and GH/IGF-I sensitive tumors. Furthermore,
GHRA administration may influence organ specific,
direct, GH action in conditions characterized by renal
damage such as diabetic nephropathy.
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